OncoSil pancreatic cancer patient registry in Italy
Part of Cancer clinical trials.
This study follows patients with pancreatic cancer who receive the OncoSil implant. It collects real-world data to learn more about how well the treatment works outside of a formal clinical trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are eligible for and receiving the OncoSil implant as part of your standard care
- You have signed a consent form to join this patient registry
- You are not taking part in any other experimental clinical trial
- You are not using any investigational (unapproved) drugs at the time of joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This observational registry tracks patients with locally advanced, unresectable pancreatic cancer who receive an OncoSil implant and then start standard chemotherapy. It may help doctors understand how the implant is used in real life and how patients do over time.
This trial tests a new treatment where doctors use imaging to guide radioactive particles directly into locally advanced pancreatic cancer tumors that haven't spread. The goal is to shrink or control the cancer with radiation delivered right to the tumor.
This study collects information from people with lung cancer who are treated at a specific hospital in Italy. The goal is to better understand the disease and improve future care.
This trial creates a program to offer personalized cancer care for patients living in central-southern Italy. It aims to use your tumor's genetic information to find the best treatment.
This study looks at people with non-metastatic, difficult-to-operate pancreatic cancer to better understand how treatment is selected and adjusted at different stages. It may help by testing a “dynamic” approach to assessment over time, before and alongside planned treatment.
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.